Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CIRCANOL vs HYDRALAZINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CIRCANOL (flupentixol) is a thioxanthene derivative that acts as a dopamine D1/D2 receptor antagonist, with higher affinity for D2 receptors, and also exhibits antagonism at serotonin 5-HT2 receptors. It modulates neurotransmission in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia and exerting antidepressant effects at low doses via presynaptic dopamine receptor blockade.
Vasodilation of arterioles by direct relaxation of vascular smooth muscle, likely involving interference with calcium movement.
Schizophrenia (maintenance therapy),Other psychotic disorders,Depression (low-dose augmentation in resistant cases)
Hypertension,Heart failure (adjunctive therapy)
4 mg orally once daily.
Oral: Initiate with 10 mg 4 times daily for 2-4 days, then increase to 25 mg 4 times daily for the remainder of the week, then titrate to 50 mg 4 times daily. Maximum daily dose: 300 mg. Intravenous: 5-20 mg IV bolus, may repeat every 20-30 minutes as needed, or continuous IV infusion 0.5-10 mg/hour.
Terminal elimination half-life is 14-18 hours in patients with normal renal function; prolonged in renal impairment.
The terminal elimination half-life of hydralazine is approximately 2–4 hours in patients with normal renal function, but it is prolonged in renal impairment (up to 7–16 hours). The antihypertensive effect often lasts longer than the half-life due to persistent binding to arteriolar receptors.
Primarily hepatic via CYP2D6 and CYP3A4, forming metabolites including N-dealkylated and sulfoxide derivatives; undergoes extensive first-pass metabolism.
Extensively metabolized in the liver via N-acetylation (N-acetyltransferase 2, NAT2) and subsequent conjugation; also metabolized by cytochrome P450 (CYP) enzymes.
Primarily renal (70-90% unchanged) with minor biliary/fecal (5-15%)
Hydralazine is primarily metabolized in the liver via N-acetylation (polymorphic) and hydroxylation. Less than 10% of the dose is excreted unchanged in urine. The major metabolites are hydralazine pyruvic acid hydrazone and other conjugates, which are excreted renally. Fecal elimination is negligible.
40-50% bound to albumin and α1-acid glycoprotein
Approximately 85–90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
1.2-1.8 L/kg; indicates extensive extravascular distribution, possibly due to tissue binding.
1.5–1.8 L/kg. This large Vd indicates extensive distribution into tissues, including arteriolar smooth muscle.
Oral: 60-75% due to first-pass metabolism
Oral bioavailability is about 26–50% due to significant first-pass metabolism. Bioavailability is higher in slow acetylators compared to rapid acetylators.
No dose adjustment required for GFR ≥30 m L/min; not recommended for use if GFR <30 m L/min.
Cr Cl 10-50 m L/min: Administer every 8 hours. Cr Cl <10 m L/min: Administer every 8-16 hours. Dose reduction may be necessary to avoid accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 2 mg once daily; Child-Pugh C: not recommended.
Child-Pugh Class A and B: No specific recommendations; use with caution. Child-Pugh Class C: Contraindicated due to risk of hepatotoxicity and reduced drug clearance.
Not approved for pediatric use; safety and efficacy not established.
Oral: 0.75-1 mg/kg/day divided every 6-12 hours, maximum 5 mg/kg/day. Intravenous: 0.1-0.2 mg/kg/dose IV every 4-6 hours as needed, maximum 0.5 mg/kg/dose (20 mg).
Start at 2 mg orally once daily; increase to 4 mg as tolerated based on response and renal function.
Initiate at lower doses (e.g., 10 mg 2-3 times daily) and titrate slowly due to increased risk of hypotension and drug accumulation; monitor renal function closely.
None
May cause a syndrome resembling systemic lupus erythematosus (SLE), especially with prolonged use or high doses.
Extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism); tardive dyskinesia with long-term use; neuroleptic malignant syndrome; QT interval prolongation; increased mortality in elderly patients with dementia-related psychosis; seizures; hepatic impairment; hematologic effects (leukopenia, neutropenia); anticholinergic effects; orthostatic hypotension; hyperprolactinemia.
May cause drug-induced lupus, peripheral neuritis (pyridoxine deficiency), myocardial infarction (precipitate angina), hypotension, tachycardia, and blood dyscrasias. Use with caution in patients with coronary artery disease, cerebrovascular disease, or renal impairment.
Comatose states; CNS depression; severe liver disease; blood dyscrasias; pheochromocytoma; known hypersensitivity to flupentixol or other thioxanthenes; concurrent use with dopamine agonists (except in Parkinson's disease psychosis).
Hypersensitivity to hydralazine, mitral valvular rheumatic heart disease, coronary artery disease, and idiopathic systemic lupus erythematosus.
Avoid grapefruit and grapefruit juice as they may increase drug levels and risk of side effects. No other significant food interactions. Maintain adequate hydration to prevent hypotension.
Hydralazine absorption is significantly increased when taken with food; it is recommended to take with meals for consistent effect. Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) if combined with MAOIs, though hydralazine itself is not an MAOI. No specific dietary restrictions otherwise.
First trimester: Evidence of human fetal harm based on retrospective studies showing increased risk of congenital anomalies (cardiac defects, neural tube defects) with first-trimester exposure. Second and third trimesters: Risk of fetal hypotension, neonatal respiratory depression, and withdrawal syndrome with chronic use; avoid near term due to risk of premature ductus arteriosus closure.
First trimester: Limited human data; animal studies show no teratogenicity. Second/third trimester: Associated with maternal hypotension and potential fetal distress; no known structural anomalies.
Small amounts excreted into breast milk (M/P ratio approximately 0.3-0.5). Considered compatible with breastfeeding due to limited oral bioavailability in infants; however, monitor infant for sedation or poor feeding.
Hydralazine is excreted into breast milk in small amounts (M/P ratio ~0.8). Considered compatible with breastfeeding by AAP; monitor infant for hypotension or drowsiness.
Increased volume of distribution and renal clearance in pregnancy may necessitate higher doses to maintain therapeutic effect; however, due to fetal risks, use lowest effective dose for shortest duration. No standard dose adjustment; individualize based on clinical response and tolerability.
Increased clearance in pregnancy may require higher doses to achieve same antihypertensive effect; start low and titrate based on blood pressure response.
Circanol (ergoloid mesylates) is a vasodilator used primarily for age-related cognitive decline. Monitor for orthostatic hypotension, especially in elderly patients. Onset of benefit may take several weeks; discontinue if no response after 3-6 months. Avoid use in patients with a history of psychosis or severe hypotension. Can be used as adjunctive therapy for dementia but not a first-line agent.
Hydralazine is a direct-acting arterial vasodilator; its antihypertensive effect is limited by reflex tachycardia and fluid retention, so it is typically used in combination with a beta-blocker and a diuretic. Slow acetylators are at increased risk of drug-induced lupus, especially with doses >200 mg/day. Administer with food to enhance bioavailability; onset of action occurs within 20-30 minutes IV. For hypertensive urgency, IV hydralazine 5-20 mg every 20-30 min is used, but avoid in suspected myocardial ischemia due to reflex tachycardia.
Take Circanol exactly as prescribed; do not stop abruptly.,Rise slowly from sitting or lying to prevent dizziness or falls.,Report any fainting, rapid heart rate, or severe headache immediately.,Avoid alcohol as it may worsen side effects like dizziness and low blood pressure.,Improvement in symptoms may take 4-12 weeks; continue medication as directed even if no immediate benefit.
Take exactly as prescribed, with food or milk to increase absorption.,Do not stop abruptly; sudden cessation can cause severe rebound hypertension.,Report symptoms like chest pain, rapid heartbeat, joint pain, rash, or fever to your doctor.,Avoid alcohol and other antihypertensives unless approved by your doctor.,Inform your doctor if you become pregnant or plan to become pregnant.,May cause dizziness; rise slowly from sitting or lying down.
No interactions on record
"Oxaprozin, a nonsteroidal anti-inflammatory drug (NSAID), can reduce the antihypertensive efficacy of hydralazine, a direct-acting vasodilator. NSAIDs inhibit prostaglandin synthesis, which can lead to sodium and fluid retention and increased vascular resistance, thereby counteracting the vasodilatory effects of hydralazine. This interaction may result in diminished blood pressure control and require dosage adjustments or alternative therapies."
"Hydralazine, a direct-acting vasodilator, may reduce the antihypertensive efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) like sulindac. NSAIDs inhibit cyclooxygenase-mediated prostaglandin synthesis, leading to sodium retention and increased vascular tone, which can antagonize the vasodilatory effects of hydralazine. This interaction may result in elevated blood pressure and diminished control of hypertension in patients receiving both agents."
"Hydralazine, a direct-acting vasodilator, may reduce the antihypertensive efficacy of Tolfenamic acid, a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits cyclooxygenase (COX) enzymes. The interaction arises because Tolfenamic acid's inhibition of COX-2 reduces synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the vascular endothelium, which counteracts the vasodilation induced by Hydralazine. Clinically, this can lead to blunted blood pressure reduction, potentially requiring dose adjustments or alternative therapies to maintain adequate hypertension control."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CIRCANOL vs HYDRALAZINE HYDROCHLORIDE, answered by our medical review team.
CIRCANOL is a Vasodilator (Peripheral) that works by CIRCANOL (flupentixol) is a thioxanthene derivative that acts as a dopamine D1/D2 receptor antagonist, with higher affinity for D2 receptors, and also exhibits antagonism at serotonin 5-HT2 receptors. It modulates neurotransmission in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia and exerting antidepressant effects at low doses via presynaptic dopamine receptor blockade.. HYDRALAZINE HYDROCHLORIDE is a Vasodilator that works by Vasodilation of arterioles by direct relaxation of vascular smooth muscle, likely involving interference with calcium movement.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CIRCANOL and HYDRALAZINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CIRCANOL is: 4 mg orally once daily.. The standard adult dose of HYDRALAZINE HYDROCHLORIDE is: Oral: Initiate with 10 mg 4 times daily for 2-4 days, then increase to 25 mg 4 times daily for the remainder of the week, then titrate to 50 mg 4 times daily. Maximum daily dose: 300 mg. Intravenous: 5-20 mg IV bolus, may repeat every 20-30 minutes as needed, or continuous IV infusion 0.5-10 mg/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CIRCANOL and HYDRALAZINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CIRCANOL is classified as Category C. First trimester: Evidence of human fetal harm based on retrospective studies showing increased risk of congenital anomalies (cardiac defects, neural tube defects) with first-trimes. HYDRALAZINE HYDROCHLORIDE is classified as Category A/B. First trimester: Limited human data; animal studies show no teratogenicity. Second/third trimester: Associated with maternal hypotension and potential fetal distress; no known stru. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.